Answers are grounded in this paper and cite their sources.
Aim The J-REGISTER study assessed outcomes and subsequent treatment in patients with EGFR mutation-positive NSCLC treated with first-line afatinib, including patients with uncommon EGFR mutations.Patients & methods This retrospective study assessed 805 patients treated with afatinib in Japan. The primary objective was time on treatment with afatinib. Other objectives included time on treatment from initiation of afatinib until the end of second-line therapy, and overall survival.Results Median time on treatment with afatinib was 13.4 months (14.3/10.1 months in patients with common/uncommon mutations). Median overall time on treatment was highest in patients who received sequential afatinib and osimertinib (32.8 months). Median overall survival was 41.2 months.Conclusion Afatinib is an effective first-line treatment option for Japanese patients with EGFR mutation-positive NSCLC.Clinical trial registration NCT04795245.
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: